(12 November 2021) Amgen Korea (GM: Sang Noh) announced the hosting of the online symposium Amgen Science Academy: Bioday (hereinafter “Amgen Bioday”) on 18th together with the Korea Health Industry Development Institute (KHIDI) (President: Soon-man Kwon), to discover and give a leg up to local companies equipped with transformative biotechnologies.
With Amgen named one of the top 10 pharmaceutical companies only 40 years after its foundation, the first ever Amgen Bioday is part of the open innovation programs designed to share Amgen’s innovative R&D technologies and strategies, and to provide a global networking venue for domestic biotechnology companies. The symposium will be attended by local companies, including start-ups, and research institutes in the biotechnology industry, and those with competitive edge will be given a networking and actual partnering opportunity with Amgen for their research technologies.
The Amgen Bioday symposium also features presentations by R&D experts from Amgen Global, who will introduce the scientific and technology areas Amgen is exploring as well as the open innovation programs. Chris Murawsky, Senior Principal Scientist, Amgen Therapeutic Discovery, will present “Biologics Discovery Techonolgies”, and Philip Tagari, Vice President of Research, will introduce the key research area of focus at Amgen through the “Therapeutic Potential of Olignucleotides” presentation. It will be followed by the introduction of Amgen’s ongoing open innovation programs, including Amgen Ventures, by Gladys Nunez Reyes, Director at Amgen Business Development.
Additionally, a separate session is planned to give participating companies and institutes a chance to virtually network with these R&D experts from Amgen Global and John Delaney, Director of Research at Amgen Therapeutic Discovery. The session is a one-to-one online meeting between Amgen Global and pharmaceutical/biotechnology companies and research institutes selected through the International BIO Pharma Cooperating Seminar & Partnering hosted by the KHIDI from 3 to 4 Nov., and more practical discussions and talks are expected where participants can explore partnering opportunities for transformative technology transactions and broader collaboration and joint R&D initiatives with Amgen.
Sang Noh, GM, Amgen Korea, said, “Amgen Science Academy: Bioday marks a very exciting opportunity to reach out to promising biotechnology companies in Korea with Amgen’s unique technical expertise and know-how in science and research. As being proactive in embracing innovation from outside is embedded in Amgen’s R&D principles, I hope this symposium can pave the way for more vibrant open innovation programs. A global biotechnology leader, Amgen will remain committed to opening up more opportunities to work with promising biotechnology companies in Korea to bring transformative new therapies to life.”
Soo-a Kim, Medical Director, Amgen Korea, said, “Amgen’s great success in becoming a global biotechnology leader with outstanding technical expertise in a short period of time is rooted in the core principle of “Be Science-based”. Growth model at Amgen can also be a good reference for innovation-powered biotechnology companies in Korea. This open innovation program is actually a chance to hear, first-hand and in detail, what Amgen Global R&D and Business Development teams wish to say about technologies, R&D strategies and pipeline at Amgen. A dedicated session for networking that can eventually lead to a long-term partnership is also planned so we would like to encourage active participation.”
Soon-wook Hwang, head of the Industrial Promotion Headquarters at KHIDI, said, “It is truly meaningful that we are able to host this open innovation program with the biotechnology leader Amgen. As the biopharmaceutical sector is very difficult to enter with immense technical challenges and hurdles to overcome, we expect networking with global pharmaceutical companies like Amgen whose growth was largely driven by its technical research prowess would go a long way for domestic biopharmaceutical companies. The Bio Pharma Business Service at the KHIDI will continue to work hard to give domestic biopharmaceutical companies even more opportunities to increase their chance of going global and advancing their R&D capabilities.”
Online pre-registration for the Amgen Science Academy: Bioday symposium is available on its website (https://bioday.kwebinar.kr/) till 6pm on 16th. Any companies, including start-ups, and research institutes in the biotechnology sector in Korea who are interested are welcome to register.
# # #
This media release was prepared to provide information on Amgen’s general business activities. Please take care not to risk potential violation of laws and regulations related to pharmaceutical advertising when referring to information contained in the media release.
# # #
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
About Amgen Korea
Amgen Korea was established in November 2015 to further develop Amgen’s clinical pipeline which offers a wide range of products for bone disease, cardiovascular, oncology/hematology, nephrology, inflammation, neuroscience treatment and biosimilars, as well as to provide innovative medicines to patients in Korea who are suffering from severe diseases. As a member of the biotechnical industry, Amgen Korea will continue to contribute to the development of the Korean pharmaceutical industry by carrying forward diversified and positive activities.
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation.
We perform a substantial amount of our commercial manufacturing activities at a few key facilities and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
Min-Jung Jung (firstname.lastname@example.org)
Heejin Ha (email@example.com)
# # #